Dr. Ali on Adjuvant Studies With Biosimilars in Oncology

Video

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

The problem with adjuvant studies, says Ali, is that they take a long time to evaluate. If adjuvant studies are mandated before biosimilars are able to be used in oncology, physicians will never get access to them. Ali explains that by the time researchers have answered the question of their efficacy, they will have moved on to other adjuvant therapies.

It makes sense to ensure that the efficacy is reasonable in the metastatic setting, says Ali. Once physicians are comfortable with that, they should be comfortable prescribing the biosimilar in the other settings that the reference drug is approved for, adds Ali. It is a personal comfort, and it should not take physicians long to determine whether these drugs are working or not, he says.

Additionally, Ali notes that physicians have to work to correct the notion that biosimilars and generics are one in the same. Ultimately, more education is needed in general if biosimilars are to flourish in the field of oncology.

Related Videos
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD
James Knight, MD
Jason Efstathiou, MD, DPhil